Tactile Systems Technology (TCMD) Announces the Publication of a Phlebology Expert Opinion Statement Recommending the Use of Pneumatic Compression for Lymphedema
Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.
Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the home treatment of patients with underserved chronic diseases, today announced the publication of a consensus statement of expert opinion. Consensus endorsements from three independent companies have been published in peer-reviewed journals Phlebology: The Journal of Venous Disease. The statement asserted that pneumatic compression should be recommended as a treatment for lymphedema, including lymphedema secondary to chronic venous insufficiency (“CVI”).
Delphi methodology was used to assess expert opinions on the available literature related to lymphedema, to provide consensus guidance on diagnosis and patient treatment pathways for this often overlooked condition. Experts from the American Venous Forum, American Venous and Lymphatic Society, and Society for Vascular Medicine evaluated a number of clinical considerations regarding risk factors, diagnosis and evaluation, and treatment of lymphedema. After analyzing the available research and data, the expert panel reached consensus on a variety of factors, including:
- Cancer, infection, chronic venous disease, and surgery are all risk factors for secondary lymphedema.
- Patients with CVI, clinical stages 3 to 6, should be treated as patients with lymphedema.
- Clinical examination is sufficient for the diagnosis of lymphedema.
- Regular use of compression garments reduces the progression of lymphedema.
- 92% of the panel agreed that sequential pneumatic compression should be recommended for patients with lymphedema.
“The recommended use of pneumatic compression has reached the highest level of consensus, and it’s encouraging to see such consistency across three independent professional societies,” said Kristie Burns, senior vice president, marketing and clinical affairs for Tactile. Medical. Dan Reuvers, President and CEO of Tactile Medical, added, “With 20 million cases of lymphedema going undiagnosed in the United States, Tactile Medical is committed to serving patients and bringing more attention to on this underdiagnosed and underserved community.
The publication in Phlebology: The Journal of Venous Diseaseaccessible via the following website: Click here
